Trial Profile
A randomised study comparing universal valganciclovir prophylaxis with quantitative polymerase chain reaction (PCR) based preemptive therapy for cytomegalovirus (CMV) disease in renal transplant recipients.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Feb 2020
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Pharmacogenomic
- Acronyms OVERT
- 12 Feb 2020 Planned End Date changed from 31 Dec 2020 to 31 May 2022.
- 31 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Jan 2017 Planned End Date changed from 30 Jun 2016 to 31 Dec 2020.